PCI Pharma Services has announced that Salim Haffar will join the company as Chief Executive Officer later this year. A global company, PCI is a full-service provider of specialist outsourced drug manufacturing, clinical trial services, and commercial packaging to the global healthcare industry.
Haffar, who has resigned as president of AptarGroup’s Aptar Pharma, will succeed Bill Mitchell, who will step out of his role as president and CEO of the company and assume the position of executive co-chairman, working closely with Mr Haffar on behalf of the board.
Haffar joins PCI with over 22 years of experience in the pharmaceutical industry. In his previous role he oversaw Aptar Pharma’s growth strategy and journey to become a leading global provider of drug delivery systems across three end markets – prescription, consumer healthcare and injectables - partnering with pharmaceutical customers to deliver medicines across several dosage forms and therapeutic areas, and operating across North America, Europe, Asia and Latin America. Haffar has also served as senior vice president, EMEA at Capsugel.
“PCI is the partner of choice for healthcare companies around the globe, and I am honoured and excited by the opportunity to lead this great organisation in its next phase of growth,” said Haffar. “With a team that includes some of the industry’s most experienced professionals, PCI is well positioned to continue expanding its portfolio of innovative service offerings, diverse customer base and extensive global supply network.”
Haffar holds a bachelor’s degree in chemical engineering from McGill university in Canada and has extensive multicultural experience having lived in Europe, the Middle East, Canada and the US.